Literature DB >> 28194060

Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma.

Yi-Yun Yao1, Yong Tang1, Yan Zhuang1, Li-Fang Zou1, Hong-Ju Dou1, Lei Wang1, Qi Zhu1.   

Abstract

This study was conducted to retrospectively investigate the efficacy and safety of pegaspargase, gemicitabine, oxaliplatin and dexamethasone (Peg-GemOD) combination chemotherapy as a first-line therapy for advanced-stage extranodal NK/T cell lymphoma (ENKTL). Eighteen patients with newly diagnosed stage III/IV ENKTL were subjected to 3-6 cycles of Peg-GemOD chemotherapy. After 3 cycles of therapy, the overall response rate was 67 % (12/18) with a complete response rate of 28 % (5/18) and a partial response rate of 39 % (7/18). The median overall survival (OS) and progression-free survival (PFS) time were 10 and 8.5 months respectively. For those responders, the median OS and PFS time were significantly better than those of non-responders (median OS, 15 vs. 10 months; P = 0.001 and median PFS, 15 vs. 7 months; P = 0.001). Furthermore, patients with low plasma EBV-DNA levels after induction chemotherapy had a remarkably longer OS and PFS time. The toxicity of Peg-GemOD regimen was acceptable.

Entities:  

Keywords:  Extranodal NK/T cell lymphoma; Gemicitabine; Induction chemotherapy; Oxaliplatin; Pegaspargase; Prognostic factors

Year:  2016        PMID： 28194060      PMCID： PMC5280855          DOI： 10.1007/s12288-016-0670-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  20 in total

1.  Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type.

Authors:  Daisuke Ennishi; Yoshinobu Maeda; Nobuharu Fujii; Eisei Kondo; Katsuji Shinagawa; Kazuma Ikeda; Koichi Ichimura; Tadashi Yoshino; Mitsune Tanimoto
Journal:  Leuk Lymphoma       Date:  2011-05-23

2.  SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.

Authors:  Yok-Lam Kwong; Won Seog Kim; Soon Thye Lim; Seok Jin Kim; Tiffany Tang; Eric Tse; Anskar Y H Leung; Chor-Sang Chim
Journal:  Blood       Date:  2012-08-23       Impact factor: 22.113

3.  A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.

Authors:  Wing H Tong; Rob Pieters; Gertjan J L Kaspers; D Maroeska W M te Loo; Marc B Bierings; Cor van den Bos; Wouter J W Kollen; Wim C J Hop; Claudia Lanvers-Kaminsky; Mary V Relling; Wim J E Tissing; Inge M van der Sluis
Journal:  Blood       Date:  2014-01-21       Impact factor: 22.113

4.  Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

Authors:  Arnaud Jaccard; Nathalie Gachard; Benoit Marin; Sylvie Rogez; Marie Audrain; Felipe Suarez; Hervé Tilly; Franck Morschhauser; Catherine Thieblemont; Loic Ysebaert; Alain Devidas; Barbara Petit; Laurence de Leval; Philippe Gaulard; Jean Feuillard; Dominique Bordessoule; Olivier Hermine
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

Review 5.  Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations.

Authors:  Maha Elnaggar; Elisa Giovannetti; Godefridus J Peters
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.

Authors:  Yoshinori Ito; Hiroshi Kimura; Yoshinobu Maeda; Chizuko Hashimoto; Fumihiro Ishida; Koji Izutsu; Noriyasu Fukushima; Yasushi Isobe; Jun Takizawa; Yuichi Hasegawa; Hajime Kobayashi; Seiichi Okamura; Hikaru Kobayashi; Motoko Yamaguchi; Junji Suzumiya; Rie Hyo; Shigeo Nakamura; Keisei Kawa; Kazuo Oshimi; Ritsuro Suzuki
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

7.  Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

Authors:  T El Gnaoui; J Dupuis; K Belhadj; J-P Jais; A Rahmouni; C Copie-Bergman; I Gaillard; M Diviné; I Tabah-Fisch; F Reyes; C Haioun
Journal:  Ann Oncol       Date:  2007-05-11       Impact factor: 32.976

8.  High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases.

Authors:  H J Kim; S M Bang; J Lee; H C Kwon; C Suh; H J Kim; J H Lee; B Y Ryoo; Y H Park; J M Kwon; S Y Oh; H R Lee; K Kim; C W Jung; K Park; W S Kim
Journal:  Bone Marrow Transplant       Date:  2006-05       Impact factor: 5.483

9.  Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells.

Authors:  M Yamaguchi; K Kita; H Miwa; K Nishii; K Oka; T Ohno; S Shirakawa; M Fukumoto
Journal:  Cancer       Date:  1995-12-01       Impact factor: 6.860

10.  Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance.

Authors:  Y-L Kwong; A W K Pang; A Y H Leung; C-S Chim; E Tse
Journal:  Leukemia       Date:  2013-07-11       Impact factor: 11.528
View more
  1 in total

1.  The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study.

Authors:  Jiwei Li; Jin Li; Meizuo Zhong; Hui Zhou; Baohua Yu
Journal:  Cancer Manag Res       Date:  2021-02-16       Impact factor: 3.989
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.